There was a significantly higher 1-year rate in the paclitaxel-eluting stent group than in the everolimus-eluting stent group of target-vessel failure ( P = 0.005 ) , spontaneous myocardial infarction ( 3.2 % vs. 1.2 % , P = 0.004 ) , stent thrombosis ( 2.1 % vs. 0.4 % , P = 0.002 ) , target-vessel revascularization ( 3.4 % vs. 1.2 % , P = 0.002 ) , and target-lesion revascularization ( 3.4 % vs. 1.2 % , P = 0.002 ) .